• 1. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 2. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 3. Enantiopure 2,6-disubstituted piperidines bearing one alkene- or alkyne-containing substituent: preparation and application to total syntheses of indolizidine-alkaloids?
  Hui Liu,Deyong Su,Guolin Cheng,Jimin Xu,Xinyan Wang,Yuefei Hu Org. Biomol. Chem., 2010,8, 1899-1904
• 4. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

Zaltoprofen: A Comprehensive Overview

Zaltoprofen, with the CAS number 74711-43-6, is a nonsteroidal anti-inflammatory drug (NSAID) that has gained significant attention in the medical community for its potent anti-inflammatory and analgesic properties. It is commonly prescribed for the management of conditions such as osteoarthritis, rheumatoid arthritis, and other inflammatory disorders. The compound's unique chemical structure and mechanism of action make it a valuable addition to the arsenal of therapeutic agents available for treating pain and inflammation.

The chemical structure of Zaltoprofen is characterized by a substituted propionamide group, which contributes to its high potency and selectivity. This structure allows Zaltoprofen to effectively inhibit cyclooxygenase (COX) enzymes, particularly COX-2, which is primarily responsible for the synthesis of prostaglandins involved in inflammation. Unlike traditional NSAIDs that non-selectively inhibit both COX-1 and COX-2, Zaltoprofen exhibits a higher degree of selectivity for COX-2, reducing the risk of gastrointestinal side effects associated with prolonged use.

Recent studies have highlighted the potential of Zaltoprofen in addressing chronic pain conditions beyond its traditional applications. For instance, research published in 2023 demonstrated its efficacy in managing post-surgical pain and reducing opioid dependence in patients undergoing major orthopedic procedures. These findings underscore the compound's versatility and its role in modern pain management strategies.

In terms of pharmacokinetics, Zaltoprofen is rapidly absorbed after oral administration, with peak plasma concentrations achieved within 1-2 hours. Its bioavailability is relatively high, making it an efficient option for patients requiring quick relief from inflammatory symptoms. The drug is metabolized primarily in the liver via cytochrome P450 enzymes, with metabolites being excreted predominantly through urine. This metabolic profile contributes to its favorable safety profile and makes it suitable for use in a wide range of patient populations.

The clinical application of Zaltoprofen extends beyond arthritis management. It has been shown to be effective in treating soft tissue injuries, such as sprains and strains, due to its potent anti-inflammatory effects. Additionally, Zaltoprofen has demonstrated promise in alleviating symptoms associated with gouty arthritis, where it helps reduce uric acid crystallization and subsequent inflammation.

One area of ongoing research focuses on optimizing dosing regimens to maximize efficacy while minimizing adverse effects. Studies are exploring the use of sustained-release formulations to improve patient compliance and reduce the frequency of administration. Furthermore, investigations into combination therapies involving Zaltoprofen and other anti-inflammatory agents are underway to enhance therapeutic outcomes for complex conditions.

From a safety perspective, Zaltoprofen generally well-tolerated by most patients. Common side effects include mild gastrointestinal discomfort and headache; however, these are typically less severe compared to those associated with non-selective NSAIDs. Long-term studies are currently being conducted to assess the compound's impact on cardiovascular health and renal function, particularly in high-risk patient populations.

In conclusion, Zaltoprofen (CAS No 74711-43-6) stands out as a highly effective anti-inflammatory agent with a robust evidence base supporting its use across various clinical settings. Its selective COX-2 inhibition mechanism, rapid onset of action, and favorable safety profile make it an invaluable tool in modern medicine. As research continues to uncover new applications and optimize therapeutic strategies involving Zaltoprofen, its role in pain management is likely to expand further.

• 103918-73-6(2-Phenylthio-5-propionylphenylacetic acid)
• 89482-01-9(Dibenzo[b,f]thiepin-2-aceticacid, 10,11-dihydro-a-methyl-10-oxo-, (aS)-)
• 105918-58-9(3-(2-methyl-9-oxothioxanthen-4-yl)propanoic Acid)
• 109239-22-7
• 89482-03-1(zaltoprofen)
• 89482-00-8(zaltoprofen)
• 83237-49-4(2-(3-(Carboxymethyl)-4-(phenylthio)-phenyl)propanoic Acid)
• 108051-48-5(Benzeneacetic acid,5-(1-oxopropyl)-2-(phenylthio)-, methyl ester)
• 58844-68-1(2-[2-(phenylsulfanyl)phenyl]propanoic acid)
• 77693-03-9(2-(8-methyl-11-oxo-10,11-dihydrodibenzo[b,f]thiepin-2-yl)propanoic acid)